Article ; Online: Nucleic acid-based markers of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
2022 Volume 41, Page(s) 101743
Abstract: The progress that has been made in the treatment of rectal cancer has mostly resulted from multimodality strategy approach that combines surgery, chemotherapy and radiotherapy. In locally advanced rectal cancer (LARC), surgery remains the primary ... ...
Abstract | The progress that has been made in the treatment of rectal cancer has mostly resulted from multimodality strategy approach that combines surgery, chemotherapy and radiotherapy. In locally advanced rectal cancer (LARC), surgery remains the primary treatment, while neoadjuvant chemoradiotherapy (nCRT) is used to downsize or downstage the tumor before surgical resection. Highly variable response to nCRT observed in LARC patients raises the need for biomarkers to enable prediction and evaluation of treatment response in a more efficient and timely manner than currently available tools. The search for predictive biomarkers continues beyond blood proteins, which have failed in subsequent validation studies. This review presents nucleic acids-based markers and their predictive potential in LARC patients. Most of the candidate biomarkers come from relatively small single-institution studies. The only candidate biomarker that emerged as relevant in more than a single study was elevated levels of Fusobacterium nucleatum nucleic acids in tumor tissue. Considering that this marker is easily accessible through non-invasive analysis of faecal samples, its predictive potential is worth further validation. The other candidate nucleic acid-based biomarkers require more consistent studies on larger cohorts before they can be considered for use in clinical setting. |
---|---|
MeSH term(s) | Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Chemoradiotherapy ; Humans ; Neoadjuvant Therapy/methods ; Neoplasms, Second Primary ; Nucleic Acids/therapeutic use ; Rectal Neoplasms/pathology ; Retrospective Studies ; Treatment Outcome |
Chemical Substances | Biomarkers, Tumor ; Nucleic Acids |
Language | English |
Publishing date | 2022-03-24 |
Publishing country | Netherlands |
Document type | Journal Article ; Review |
ZDB-ID | 1107810-8 |
ISSN | 1879-3320 ; 0960-7404 |
ISSN (online) | 1879-3320 |
ISSN | 0960-7404 |
DOI | 10.1016/j.suronc.2022.101743 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 3409: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.